CG
VIRX

Cutler Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Cutler Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6
Closed – – 6892
2017
Q2 		$0 Buy
+6
New +$689 ﹤0.01% 7240
2017
Q1 		– Sell
-5
Closed – – 7391
2016
Q4 		$0 Hold
5
– – ﹤0.01% 7483
2016
Q3 		$0 Hold
5
– – ﹤0.01% 7518
2016
Q2 		$0 Hold
5
– – ﹤0.01% 7432
2016
Q1 		$0 Sell
5
-1
-17% -$152 ﹤0.01% 7362
2015
Q4 		$1K Buy
+6
New +$1.12K ﹤0.01% 6144

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Cutler Group's VIRX Position: Q3 2017 in Review

Cutler Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2017, closing a stake of 6 shares.

Cutler Group first reported a position in VIRX in Q4 2015 and held it in 6 quarters. The position peaked at $1K in Q4 2015. 35 funds tracked by Wall St. Rank hold VIRX as of Q3 2017.

  • Cutler Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Cutler Group sold 6 Viracta Therapeutics, Inc. Common Stock shares in Q3 2017.
  • Cutler Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2015 and held it in 6 quarters.
  • Cutler Group's Viracta Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2015.
  • 35 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Cutler Group's 13F filing for Q3 2017, filed 17 Oct 2017.